Comparative Pharmacology
Head-to-head clinical analysis: FRAGMIN versus HEPARIN SODIUM 20 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: FRAGMIN versus HEPARIN SODIUM 20 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
FRAGMIN vs HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fragmin (dalteparin) is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and, to a lesser extent, thrombin, thereby preventing thrombus formation.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing fibrin formation. Dextrose 5% provides caloric support.
Deep vein thrombosis prophylaxis: 2500 IU subcutaneously once daily, starting 1-2 hours before surgery and continuing postoperatively for 5-10 days or until ambulatory. Treatment of acute DVT: 200 IU/kg subcutaneously once daily, or 100 IU/kg twice daily. Unstable angina/NSTEMI: 120 IU/kg subcutaneously every 12 hours (max 10,000 IU per dose) with aspirin.
IV: Initial bolus 80 units/kg, then continuous infusion at 18 units/kg/hr; adjust based on aPTT. Typical concentration: 20,000 units heparin in 500 mL D5W (40 units/mL).
None Documented
None Documented
2-4 hours (anti-Xa activity) after subcutaneous administration; prolonged in renal impairment (creatinine clearance <30 mL/min: up to 6-12 hours)
30–150 minutes (mean 90 min) for continuous IV infusion; shorter with higher doses due to saturable clearance. Prolonged in hepatic or renal impairment.
Primarily renal excretion (up to 70% as unchanged drug via glomerular filtration); minor biliary/fecal elimination (<15%)
Renal: negligible at therapeutic doses; hepatic metabolism to uroheparin and low molecular weight species; biliary/fecal: minimal. Clearance is dose-dependent and saturable.
Category C
Category A/B
Anticoagulant
Anticoagulant